Loading...
Loading...
In a report published Wednesday, Deutsche Bank reiterated its Hold rating on Boston Scientific Corporation
BSX, and slightly raised its price target from $6.70 to $7.20.
Deutsche Bank noted, “Accelerating growth seems more credible now, but it's about execution. Boston Scientific held its last investor meeting in the fall of 2010. Then, as now, the company targeted accelerating top line growth. With several acquisitions and restructuring, we believe the company is in better financial shape today though there's still a significant amount of risk on executing on the pipeline and with the core markets remaining stable. We left the analyst meeting more optimistic on the outlook and are raising our price target. However, given the stock's recent move (up 32.5% YTD) and current price, we maintain our Hold rating.”
Boston Scientific Corporation closed on Tuesday at $7.59.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in